Cite
HARVARD Citation
Bachert, C. et al. (n.d.). A new intranasal therapy (MP29‐02*) is more effective than current firstline therapy regardless of season, symptom or severity.. Clinical and translational allergy. 5 (4), p. n/a. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Bachert, C. et al. (n.d.). A new intranasal therapy (MP29‐02*) is more effective than current firstline therapy regardless of season, symptom or severity.. Clinical and translational allergy. 5 (4), p. n/a. [Online].